TBP Stock Forecast & Price: Based on the Tetra Bio Pharma Inc stock forecasts from 1 analysts, the average analyst target price for Tetra Bio Pharma Inc is CAD 0.00 over the next 12 months. Tetra Bio Pharma Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Tetra Bio Pharma Inc is Bearish, which is based on 1 positive signals and 7 negative signals. At the last closing, Tetra Bio Pharma Inc’s stock price was CAD 0.04. Tetra Bio Pharma Inc’s stock price has changed by -22.22% over the past week, -36.36% over the past month and -85.11% over the last year.

2. Page 1 of 9 Any information in this report is not , and should not be regarded as investment advice or as a recommendation regarding any particular security or course of
action. We recommend seeking a licensed professional for investment advice.
TBP:CA:TSX (Tetra Bio Pharma Inc)
Biotechnology | TSX | Common Stock
Values as of 16th Oct, 2022
Stock Target Advisor
Detailed Stock Report
Report Date: 17th October, 2022
Last Close
CAD 0.04
Change
+0.00(+0.00%)
Market Cap
CAD 0.01B
1 Yr Capital
Gain
-85.11%
1 Yr Dividend Return
N/A
1 Yr Total
Return
-85.11%
Earning
Growth (5
yr)
-241.39%
Average Target Price
A PHP Error was encountered
Severity: Warning
Message: A non-numeric value encountered
Filename: views/stock_detail_pdf_report_ready.php
Line Number: 174
Backtrace:
File:
/var/www/html/stocktarget/application/views/stock_detail_pdf_report_ready.php
Line: 174
Function: _error_handler
File: /var/www/html/stocktarget/application/controllers/Detail_page_report.php
Line: 244
Function: view
File: /var/www/html/stocktarget/index.php
Line: 316
Function: require_once
N/A
Average Analyst
Rating
Strong Buy
Fundamental
Analysis
Bearish
Our view of the stock is Bearish with a score of 1.2 out of 10, where 0 is very bearish and 10 very bullish
What to like
Low volatility
The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although
stability is good, also keep in mind it can limit returns.
What to not like
Low market capitalization
This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique
technology or market which can help it grow or get acquired in future.
Poor risk adjusted returns
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Low Earnings Growth
This stock has shown below median earnings growth in the previous 5 years compared to its sector

3. Page 2 of 9 Any information in this report is not , and should not be regarded as investment advice or as a recommendation regarding any particular security or course of
action. We recommend seeking a licensed professional for investment advice.
TBP:CA:TSX (Tetra Bio Pharma Inc)
Biotechnology | | Common Stock
Stock Target Advisor
Detailed Stock Report
Report Date: 17th October, 2022
Adjusted Closing Share Volume
Relative Returns Relative Performance (Total Returns)
Security Capital Gain Dividend Return Total Return
TBP:CA
Tetra Bio Pharma Inc
-85.1% 0 -85.1%
XIU:CA
iShares S&P/TSX 60
-11.5% +2.7% -8.8%
Company Overview
Tetra Bio-Pharma Inc., a biopharmaceutical company, engages in the discovery and development of cannabinoid-derived drugs for
inflammation, pain, ophthalmology, and oncology. The company develops PLENITUDE to treat cancer-related pain in advanced cancer
patients; REBORN for the treatment of breakthrough cancer pain; Reduvo for chemotherapy-induced nausea and vomiting; ARDS-003 for the
treatment of sepsis and prevention of acute respiratory distress syndrome; and SERENITY to treat cancer cachexia. It also develops PPP003
for painful dry eye and uveitis pain; and HCC011 for hepatocellular carcinoma. Tetra Bio-Pharma Inc. has an agreement with Cellvera Global
Holdings LLC for the co-development of ARDS-003 as a combination product with Qifenda 400MG (Favipiravir), a commercial-stage broad-
spectrum antiviral drug. The company is headquartered in Orléans, Canada.

4. Page 3 of 9 Any information in this report is not , and should not be regarded as investment advice or as a recommendation regarding any particular security or course of
action. We recommend seeking a licensed professional for investment advice.
Company Website
https://www.tetrabiopharma.com
Address
2316 St. Joseph Boulevard, Orléans, ON, Canada, K1C 1E8
Fiscal Year End
December
Employees
33
Technical Indicators
Value Value
Beta 2.09 52 Week High 0.25
Short Ratio 0.60 52 Week Low 0.03
Shorted Shares 334,150 200 Day Moving Average 0.07
Shorted Shares Previous Month 233,598 50 Day Moving Average 0.05
Shares Held By Insiders 118.90% Short Percentage N/A
Shares Held by Institutions N/A Dividend Yield N/A

5. Page 4 of 9 Any information in this report is not , and should not be regarded as investment advice or as a recommendation regarding any particular security or course of
action. We recommend seeking a licensed professional for investment advice.
TBP:CA:TSX (Tetra Bio Pharma Inc)
Biotechnology | | Common Stock
Stock Target Advisor
Detailed Stock Report
Report Date: 17th October, 2022
Market Performance
Market Performance vs. Industry / Classification (Biotechnology) Market Performance vs. Exchange (Nasdaq Global Select)
Value Sector Median
Percentile
Rank
Grade Market Median Percentile Rank Grade
YTD
Capital Gain -72.00% -43.5% 6% -17.5% 2%
Dividend Return N/A N/A N/A 2.0% N/A
Total Return -72.00% -43.5% 6% -16.3% 2%
Trailing 12 Months
Capital Gain -85.11% -61.5% 11% -16.0% 1%
Dividend Return N/A N/A N/A 2.4% N/A
Total Return -85.11% -61.5% 11% -14.5% 1%
Trailing 5 Years
Capital Gain -95.00% -69.1% 13% -4.8% 1%
Dividend Return N/A N/A N/A 10.8% N/A
Total Return -95.00% -69.1% 13% 6.3% 1%
Average Annual (5 Year Horizon)
Capital Gain -31.94% -3.8% 11% 2.9% 1%
Dividend Return N/A N/A N/A 1.8% N/A
Total Return -31.94% -3.8% 11% 5.0% 1%
Risk Return Profile
Volatility (Standard
Deviation)
40.64% 75.3% 89% 17.6% 22%
Risk Adjusted Return -78.60% N/A 6% 30.1% 3%
Market Capitalization 0.01B 0.05B 16% 0.24B 12%

6. Page 5 of 9 Any information in this report is not , and should not be regarded as investment advice or as a recommendation regarding any particular security or course of
action. We recommend seeking a licensed professional for investment advice.
Key Financial Ratios
Ratios vs. Industry / Classification (Computer Hardware) Ratios vs. Exchange (Nasdaq Global Select)
Value Sector Median
Percentile
Rank
Grade Market Median Percentile Rank Grade
Market Value
peratio N/A 24.8 N/A 13.0 N/A
pbratio 48.2 4.6 6% 1.2 1%
pcfratio -0.6 -3.7 16% 5.1 73%
pfcfratio -0.4 -2.5 32% 4.6 72%
Management Effectiveness
retequity -248.69% -75.1% 29% 8.2% 3%
retinvcap -362.37% -69.1% 11% 4.2% 0%
retass -37.68% -37.7% 53% 2.2% 4%
debtequityratio N/A 31.7% N/A 49.5% N/A
Technical Ratios
yield N/A N/A N/A 3.9% N/A
sratio 0.60 2.46 89% 3.06 80%
spercent 0.43% 0.3% 38% 0.8% 61%
beta 2.09 1.45 17% 1.04 10%

7. Page 6 of 9 Any information in this report is not , and should not be regarded as investment advice or as a recommendation regarding any particular security or course of
action. We recommend seeking a licensed professional for investment advice.
TBP:CA:TSX (Tetra Bio Pharma Inc)
Biotechnology | | Common Stock
Stock Target Advisor
Detailed Stock Report
Report Date: 17th October, 2022
Recent Analyst Ratings
Price Action Rating Action Analyst Rating Price date
Assigns STA Research Speculative Buy CAD 27 2022-10-14

8. Page 7 of 9 Any information in this report is not , and should not be regarded as investment advice or as a recommendation regarding any particular security or course of
action. We recommend seeking a licensed professional for investment advice.
TBP:CA:TSX (Tetra Bio Pharma Inc)
Biotechnology | | Common Stock
Stock Target Advisor
Detailed Stock Report
Report Date: 17th October, 2022
Annual Financial (CAD)

9. Page 8 of 9 Any information in this report is not , and should not be regarded as investment advice or as a recommendation regarding any particular security or course of
action. We recommend seeking a licensed professional for investment advice.
TBP:CA:TSX (Tetra Bio Pharma Inc)
Biotechnology | | Common Stock
Stock Target Advisor
Detailed Stock Report
Report Date: 17th October, 2022
Quarterly Financial (CAD)

10. Page 9 of 9 Any information in this report is not , and should not be regarded as investment advice or as a recommendation regarding any particular security or course of
action. We recommend seeking a licensed professional for investment advice.
TBP:CA:TSX (Tetra Bio Pharma Inc)
Biotechnology | | Common Stock
Stock Target Advisor
Detailed Stock Report
Report Date: 17th October, 2022
Largest Industry Peers for Biotechnology
Symbol Company Name Price(Change) Market Cap
TRIL:CA Trillium Therapeutics Inc N/A CAD 2.43B
BLU:CA BELLUS Health Inc. N/A CAD 1.76B
LMNL:CA Liminal BioSciences Inc N/A CAD 0.54B
FRX:CA Fennec Pharmaceuticals Inc N/A CAD 0.28B
SVA:CA Sernova Corp N/A CAD 0.24B
BCT:CA Briacell Therapeutics Corp N/A CAD 0.14B
ONC:CA Oncolytics Biotech Inc N/A CAD 0.10B
MDNA:CA Medicenna Therapeutics Corp N/A CAD 0.08B
APS:CA Aptose Biosciences Inc N/A CAD 0.07B
MBX:CA Microbix Biosystems Inc. N/A CAD 0.07B
The Stock Target Advisor platform run millions of calculations every day on over 30,000 Canadian and American stocks, comparing and
ranking their financial and market performance against their sectors and exchange.
We represent the percentile ranking using the following grading system.
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%